PARTNER
검증된 파트너 제휴사 자료

Warfarin과 Propafenone 병용 시 용량 조절 기준 설정 (Proposal for Warfarin Dosage Guideline during Warfarin-Propafenone Combination Therapy)

12 페이지
기타파일
최초등록일 2025.05.30 최종저작일 2013.02
12P 미리보기
Warfarin과 Propafenone 병용 시 용량 조절 기준 설정
  • 미리보기

    서지정보

    · 발행기관 : 한국병원약사회
    · 수록지 정보 : 병원약사회지 / 30권 / 1호 / 52 ~ 63페이지
    · 저자명 : 박선미, 민경아, 인용원, 이영미

    초록

    Oral anticoagulation therapy with warfarin is effective in the prevention of stroke during atrial fibrillation, but it needs careful monitoring because of its narrow therapeutic range and complexity of interaction with other medications. Propafenone is an antiarrhythmic agent classified in the class I c category. A previous study provided clinical evidence for a possible interaction between warfarin and propafenone. The addition of propafenone can potentiate the anticoagulant effect of warfarin so the previous study recommended a close monitoring and reduction of warfarin dosage when co-administered with propafenone. However, no reports have established an appropriate warfarin dosage guideline. Therefore, this study was conducted to determine the appropriate dosage of warfarin when co-administered with propafenone in regards to developing a practical guideline.
    A retrospective analysis was done for all patients who received propafenone, seen by the anticoagulation service (ACS) at Samsung Medical Center from January 1, 2008 to January 31, 2011.
    Patients who had consistent therapeutic INR values (1.8-3.2) with the same dose of warfarin for at least 1 month and who had not received any drugs known to alter INR values or interact with warfarin were included in the study.
    A total of twenty four patients met the inclusion criteria. The 1st ACS follow-ups were performed on day 7.63±3.85 and increases in INR were observed. The reduction rate in the warfarin dose for maintaining therapeutic INR was 10.08±6.79%. There was a significant difference in the reduction of the warfarin dose between the baseline and the 1st ACS follow-up. No significant differences were observed in the reduction of warfarin dose between the 1st ACS follow-up and 2nd ACS follow-up. Although no major bleeding was observed in the study group, 2 cases of minor bleeding (bruise and gingival bleeding) occurred during the study period. Based on these findings, we recommend a 10-15% reduction in the dose of warfarin at the time propafenone treatment is started and INR values should be determined on day 7-10 to ensure that therapeutic INR levels are maintained.
    This study provides a clinically available warfarin dosage guideline in the concomitant use of propafenone and warfarin. In addition, based on the results of this study, additional prospective study should be needed.

    영어초록

    Oral anticoagulation therapy with warfarin is effective in the prevention of stroke during atrial fibrillation, but it needs careful monitoring because of its narrow therapeutic range and complexity of interaction with other medications. Propafenone is an antiarrhythmic agent classified in the class I c category. A previous study provided clinical evidence for a possible interaction between warfarin and propafenone. The addition of propafenone can potentiate the anticoagulant effect of warfarin so the previous study recommended a close monitoring and reduction of warfarin dosage when co-administered with propafenone. However, no reports have established an appropriate warfarin dosage guideline. Therefore, this study was conducted to determine the appropriate dosage of warfarin when co-administered with propafenone in regards to developing a practical guideline.
    A retrospective analysis was done for all patients who received propafenone, seen by the anticoagulation service (ACS) at Samsung Medical Center from January 1, 2008 to January 31, 2011.
    Patients who had consistent therapeutic INR values (1.8-3.2) with the same dose of warfarin for at least 1 month and who had not received any drugs known to alter INR values or interact with warfarin were included in the study.
    A total of twenty four patients met the inclusion criteria. The 1st ACS follow-ups were performed on day 7.63±3.85 and increases in INR were observed. The reduction rate in the warfarin dose for maintaining therapeutic INR was 10.08±6.79%. There was a significant difference in the reduction of the warfarin dose between the baseline and the 1st ACS follow-up. No significant differences were observed in the reduction of warfarin dose between the 1st ACS follow-up and 2nd ACS follow-up. Although no major bleeding was observed in the study group, 2 cases of minor bleeding (bruise and gingival bleeding) occurred during the study period. Based on these findings, we recommend a 10-15% reduction in the dose of warfarin at the time propafenone treatment is started and INR values should be determined on day 7-10 to ensure that therapeutic INR levels are maintained.
    This study provides a clinically available warfarin dosage guideline in the concomitant use of propafenone and warfarin. In addition, based on the results of this study, additional prospective study should be needed.

    참고자료

    · 없음
  • 자주묻는질문의 답변을 확인해 주세요

    해피캠퍼스 FAQ 더보기

    꼭 알아주세요

    • 자료의 정보 및 내용의 진실성에 대하여 해피캠퍼스는 보증하지 않으며, 해당 정보 및 게시물 저작권과 기타 법적 책임은 자료 등록자에게 있습니다.
      자료 및 게시물 내용의 불법적 이용, 무단 전재∙배포는 금지되어 있습니다.
      저작권침해, 명예훼손 등 분쟁 요소 발견 시 고객센터의 저작권침해 신고센터를 이용해 주시기 바랍니다.
    • 해피캠퍼스는 구매자와 판매자 모두가 만족하는 서비스가 되도록 노력하고 있으며, 아래의 4가지 자료환불 조건을 꼭 확인해주시기 바랍니다.
      파일오류 중복자료 저작권 없음 설명과 실제 내용 불일치
      파일의 다운로드가 제대로 되지 않거나 파일형식에 맞는 프로그램으로 정상 작동하지 않는 경우 다른 자료와 70% 이상 내용이 일치하는 경우 (중복임을 확인할 수 있는 근거 필요함) 인터넷의 다른 사이트, 연구기관, 학교, 서적 등의 자료를 도용한 경우 자료의 설명과 실제 자료의 내용이 일치하지 않는 경우
문서 초안을 생성해주는 EasyAI
안녕하세요. 해피캠퍼스의 방대한 자료 중에서 선별하여 당신만의 초안을 만들어주는 EasyAI 입니다.
저는 아래와 같이 작업을 도와드립니다.
- 주제만 입력하면 목차부터 본문내용까지 자동 생성해 드립니다.
- 장문의 콘텐츠를 쉽고 빠르게 작성해 드립니다.
- 스토어에서 무료 캐시를 계정별로 1회 발급 받을 수 있습니다. 지금 바로 체험해 보세요!
이런 주제들을 입력해 보세요.
- 유아에게 적합한 문학작품의 기준과 특성
- 한국인의 가치관 중에서 정신적 가치관을 이루는 것들을 문화적 문법으로 정리하고, 현대한국사회에서 일어나는 사건과 사고를 비교하여 자신의 의견으로 기술하세요
- 작별인사 독후감
해캠 AI 챗봇과 대화하기
챗봇으로 간편하게 상담해보세요.
2025년 07월 26일 토요일
AI 챗봇
안녕하세요. 해피캠퍼스 AI 챗봇입니다. 무엇이 궁금하신가요?
11:27 오전